VBI Vaccines, Inc. (VBIV) Stock Rating Upgraded by Zacks Investment Research

VBI Vaccines, Inc. (NASDAQ:VBIV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday, October 18th.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

A number of other equities analysts also recently weighed in on VBIV. ValuEngine downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Shares of VBI Vaccines (NASDAQ VBIV) traded up $0.02 during trading hours on Wednesday, hitting $4.22. The stock had a trading volume of 426,494 shares, compared to its average volume of 223,453. VBI Vaccines has a one year low of $2.78 and a one year high of $6.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.00 and a quick ratio of 1.91.

TRADEMARK VIOLATION WARNING: “VBI Vaccines, Inc. (VBIV) Stock Rating Upgraded by Zacks Investment Research” was reported by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/zacks-investment-research-upgrades-vbi-vaccines-inc-vbiv-to-hold/1722822.html.

In other news, CEO Jeff Baxter acquired 10,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average price of $3.28 per share, with a total value of $32,800.00. Following the completion of the acquisition, the chief executive officer now owns 110,255 shares in the company, valued at approximately $361,636.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Steven Gillis bought 300,000 shares of the stock in a transaction on Monday, October 30th. The shares were acquired at an average cost of $3.05 per share, with a total value of $915,000.00. Following the acquisition, the director now directly owns 46,916 shares in the company, valued at approximately $143,093.80. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,078,738 shares of company stock valued at $12,444,511. Corporate insiders own 34.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp bought a new stake in VBI Vaccines in the 2nd quarter valued at $883,000. State Street Corp bought a new stake in VBI Vaccines in the 2nd quarter valued at $831,000. KCG Holdings Inc. bought a new stake in VBI Vaccines in the 1st quarter valued at $512,000. Goldman Sachs Group Inc. bought a new stake in VBI Vaccines in the 1st quarter valued at $383,000. Finally, Bank of Montreal Can lifted its position in VBI Vaccines by 8.6% during the 2nd quarter. Bank of Montreal Can now owns 63,398 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 5,000 shares in the last quarter. 31.37% of the stock is currently owned by institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.